Survival of colorectal cancer patients in Brunei Darussalam: comparison between 2002-09 and 2010-17.
Adult
Age Distribution
Age Factors
Aged
Brunei
/ epidemiology
Colon
/ pathology
Colonic Neoplasms
/ ethnology
Colorectal Neoplasms
/ mortality
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Proportional Hazards Models
Rectal Neoplasms
/ ethnology
Retrospective Studies
Survival Rate
Time Factors
Young Adult
Brunei Darussalam
Cancer registry
Colorectal cancer
Prognosis
Survival rate
Survival time
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Apr 2021
30 Apr 2021
Historique:
received:
21
12
2020
accepted:
19
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide. It is the second leading cause of cancer death in men and women in Brunei Darussalam in 2017, posing a major burden on society. This retrospective cohort study (n = 1035 patients diagnosed with CRC in Brunei Darussalam from 1st January 2002 until 31st December 2017) aims to compare the overall survival rates of CRC patients (2002-2017), to compare survival rates between two study periods (2002-2009 and 2010-2017) and to identify prognostic factors of CRC. Kaplan-Meier estimator and log-rank tests were performed to analyse the overall survival rates of CRC patients. Multiple Cox regression was performed to determine the prognostic factors of CRC with adjusted hazard ratios (Adj. HRs) reported. The 1-, 3- and 5-year survival rates of CRC patients are 78.6, 62.5, and 56.0% respectively from 2002 to 2017. The 1-, 3-, and 5-year survival rates of CRC patients for 2002-2009 are 82.2, 69.6, and 64.7%; 77.0, 59.1, and 51.3% for 2010-2017 respectively. A significant difference in CRC patients' survival rate was observed between the two study periods, age groups, ethnic groups, cancer stages, and sites of cancer (p < 0.05). The Adjusted Hazard Ratios (Adj. HRs) were significantly higher in the 2010-17 period (Adj. HR = 1.78, p < 0.001), older age group ( ≥ 60 years) (Adj. HR = 1.93, p = 0.005), distant cancer (Adj. HR = 4.69, p < 0.010), tumor at transverse colon and splenic flexure of colon (Adj. HR = 2.44, p = 0.009), and lower in the Chinese(Adj. HR = 0.63, p = 0.003). This study highlights the lower survival rates of CRC patients in 2010-2017, Malays, older patients, distant cancer, and tumors located at the latter half of the proximal colon (transverse colon), and predominantly LCRC (splenic flexure, descending colon, sigmoid colon, overlapping lesion colon and colon (NOS), as well as the rectosigmoid junction and rectum (NOS)). Age, ethnicity, cancer stage, and tumor location are significant prognostic factors for CRC. These findings underscore the importance of public health policies and programmes to enhance awareness on CRC from screening to developing strategies for early detection and management, to reduce CRC-associated mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide. It is the second leading cause of cancer death in men and women in Brunei Darussalam in 2017, posing a major burden on society.
METHODS
METHODS
This retrospective cohort study (n = 1035 patients diagnosed with CRC in Brunei Darussalam from 1st January 2002 until 31st December 2017) aims to compare the overall survival rates of CRC patients (2002-2017), to compare survival rates between two study periods (2002-2009 and 2010-2017) and to identify prognostic factors of CRC. Kaplan-Meier estimator and log-rank tests were performed to analyse the overall survival rates of CRC patients. Multiple Cox regression was performed to determine the prognostic factors of CRC with adjusted hazard ratios (Adj. HRs) reported.
RESULTS
RESULTS
The 1-, 3- and 5-year survival rates of CRC patients are 78.6, 62.5, and 56.0% respectively from 2002 to 2017. The 1-, 3-, and 5-year survival rates of CRC patients for 2002-2009 are 82.2, 69.6, and 64.7%; 77.0, 59.1, and 51.3% for 2010-2017 respectively. A significant difference in CRC patients' survival rate was observed between the two study periods, age groups, ethnic groups, cancer stages, and sites of cancer (p < 0.05). The Adjusted Hazard Ratios (Adj. HRs) were significantly higher in the 2010-17 period (Adj. HR = 1.78, p < 0.001), older age group ( ≥ 60 years) (Adj. HR = 1.93, p = 0.005), distant cancer (Adj. HR = 4.69, p < 0.010), tumor at transverse colon and splenic flexure of colon (Adj. HR = 2.44, p = 0.009), and lower in the Chinese(Adj. HR = 0.63, p = 0.003).
CONCLUSION
CONCLUSIONS
This study highlights the lower survival rates of CRC patients in 2010-2017, Malays, older patients, distant cancer, and tumors located at the latter half of the proximal colon (transverse colon), and predominantly LCRC (splenic flexure, descending colon, sigmoid colon, overlapping lesion colon and colon (NOS), as well as the rectosigmoid junction and rectum (NOS)). Age, ethnicity, cancer stage, and tumor location are significant prognostic factors for CRC. These findings underscore the importance of public health policies and programmes to enhance awareness on CRC from screening to developing strategies for early detection and management, to reduce CRC-associated mortality.
Identifiants
pubmed: 33926405
doi: 10.1186/s12885-021-08224-6
pii: 10.1186/s12885-021-08224-6
pmc: PMC8086270
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
477Références
Ann Coloproctol. 2018 Aug;34(4):212-221
pubmed: 30208684
Int J Cancer. 2009 May 15;124(10):2406-15
pubmed: 19142968
Clin Cancer Res. 2009 Oct 15;15(20):6391-7
pubmed: 19789331
Nutr Rev. 2012 Jan;70(1):3-21
pubmed: 22221213
BMC Cancer. 2014 Jun 17;14:446
pubmed: 24938667
ANZ J Surg. 2007 Jun;77(6):446-9
pubmed: 17501884
Cancers (Basel). 2018 Jan 30;10(2):
pubmed: 29385712
CA Cancer J Clin. 2008 May-Jun;58(3):161-79
pubmed: 18443206
Prev Chronic Dis. 2018 Aug 23;15:E106
pubmed: 30148425
JAMA. 2008 Dec 17;300(23):2765-78
pubmed: 19088354
Carcinogenesis. 2014 Jul;35(7):1516-22
pubmed: 24648381
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):913-933
pubmed: 31648977
BMJ. 2002 Apr 20;324(7343):931-2
pubmed: 11964327
J Gastrointest Oncol. 2015 Dec;6(6):605-12
pubmed: 26697191
Int J Cancer. 2002 Oct 10;101(5):403-8
pubmed: 12216066
Intest Res. 2014 Jul;12(3):184-93
pubmed: 25349592
Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):286-94
pubmed: 23169929
JAMA Intern Med. 2015 May;175(5):767-76
pubmed: 25751512
PLoS One. 2013 Jul 05;8(7):e68077
pubmed: 23861851
Br J Cancer. 2011 May 24;104(11):1779-85
pubmed: 21559011
Nat Commun. 2019 May 14;10(1):2154
pubmed: 31089142
Epidemiol Health. 2016 Mar 09;38:e2016007
pubmed: 26971697
Practitioner. 2012 Jul-Aug;256(1753):15-8, 2
pubmed: 22988701
Asian Pac J Cancer Prev. 2015;16(8):3279-83
pubmed: 25921132
Clin Adv Hematol Oncol. 2020 May;18(5):253-257
pubmed: 32628652
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):894-895
pubmed: 31648973
World J Surg Oncol. 2014 Dec 02;12:370
pubmed: 25466394
PLoS One. 2012;7(12):e52457
pubmed: 23300677
Eur J Clin Nutr. 2019 Mar;73(3):366-386
pubmed: 30050075
Int J Mol Sci. 2017 Jan 19;18(1):
pubmed: 28106826
Asian Pac J Cancer Prev. 2015;16(12):5063-7
pubmed: 26163642
J BUON. 2019 Sep-Oct;24(5):1845-1851
pubmed: 31786846
BMC Cancer. 2017 May 18;17(1):339
pubmed: 28521746
Int J Cancer. 2002 May 20;99(3):460-5
pubmed: 11992418
Asia Pac J Public Health. 2017 Nov;29(8):635-648
pubmed: 29082745
World J Gastrointest Oncol. 2015 Dec 15;7(12):422-33
pubmed: 26690833
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Asian J Surg. 2017 Nov;40(6):481-489
pubmed: 27492344
BMJ Open. 2015 Oct 09;5(10):e008448
pubmed: 26453591
Arq Bras Cir Dig. 2019 Dec 20;32(4):e1479
pubmed: 31859932
Nat Rev Cancer. 2020 Feb;20(2):125-138
pubmed: 31848467
Singapore Med J. 2009 Nov;50(11):1085-9
pubmed: 19960165
Intest Res. 2019 Jul;17(3):317-329
pubmed: 31085968
Cochrane Database Syst Rev. 2012 Aug 15;(8):CD008997
pubmed: 22895981
Cancer Med. 2018 Apr;7(4):1141-1150
pubmed: 29533001
N Engl J Med. 1988 Sep 1;319(9):525-32
pubmed: 2841597
Int J Clin Exp Med. 2015 May 15;8(5):6878-89
pubmed: 26221225
J Geriatr Oncol. 2018 Jul;9(4):382-392
pubmed: 29396234
Prz Gastroenterol. 2019;14(1):26-38
pubmed: 30944675
BMC Cancer. 2018 Sep 20;18(1):906
pubmed: 30236083
World J Gastroenterol. 2013 Sep 14;19(34):5651-7
pubmed: 24039357
Asian Pac J Cancer Prev. 2015;16(9):3927-30
pubmed: 25987062
Medicine (Baltimore). 2017 Oct;96(42):e8241
pubmed: 29049212
Ann Oncol. 2011 Sep;22(9):1958-1972
pubmed: 21307158
Eur J Cancer. 2017 Oct;84:69-80
pubmed: 28787661
J Public Health (Oxf). 2008 Jun;30(2):194-201
pubmed: 18445612
J Clin Oncol. 2011 Nov 20;29(33):4401-9
pubmed: 21969498
World J Gastrointest Oncol. 2012 Apr 15;4(4):71-5
pubmed: 22532879
Dis Colon Rectum. 2010 Jan;53(1):57-64
pubmed: 20010352
Gastroenterology Res. 2018 Aug;11(4):264-273
pubmed: 30116425
Perm J. 2011 Fall;15(4):30-8
pubmed: 22319413
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gastroenterology. 2010 Jun;138(6):2044-58
pubmed: 20420945
Ann Surg Treat Res. 2019 Jun;96(6):296-304
pubmed: 31183334
Hum Mol Genet. 2014 Jul 15;23(14):3898-905
pubmed: 24562164
Clin Colon Rectal Surg. 2009 Nov;22(4):191-7
pubmed: 21037809
Clin Colon Rectal Surg. 2018 May;31(3):168-178
pubmed: 29720903
J Gastroenterol Hepatol. 2008 Mar;23(3):418-23
pubmed: 17532785
World J Gastroenterol. 2014 May 28;20(20):6055-72
pubmed: 24876728
J Geriatr Oncol. 2016 Jul;7(4):281-92
pubmed: 27197919